FDA approval for CliniMACS CD34 Reagent System for prevention of graft-versus-host disease in the treatment of acute myeloid leukemia Miltenyi Biotec has announced that the U.S. Food and Drug Administration has approved the company's CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft- versus-host disease in ... (more)
http://www.medicalnewstoday.com/releases/271757.php
http://www.medicalnewstoday.com/releases/271757.php
No comments:
Post a Comment